Transforming healthcare – Healthy Returns Summit with Eli Lilly CEO David Ricks

While at the forefront of developing Covid-19 antibodies, Eli Lilly has doubled down on R&D, digital analytics and medical innovation. With a pipeline of new drugs in the works to treat conditions ranging from Alzheimer's to diabetes and migraines, the company is focusing hard on finding new ways to collaborate with partners and governments to deliver groundbreaking treatments in record time. Chairman and CEO David Ricks joins Meg Tirrell at the Healthy Returns Summit on May 11.